Comparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Ironwood Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.87 times
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 473.21%, its profits have risen by 739% ; the PEG ratio of the company is 0
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Ironwood Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ironwood Pharmaceuticals, Inc.
438.72%
-0.39
106.43%
S&P 500
20.78%
1.67
13.28%
Quality key factors
Factor
Value
Sales Growth (5y)
-5.33%
EBIT Growth (5y)
-5.59%
EBIT to Interest (avg)
12.02
Debt to EBITDA (avg)
1.99
Net Debt to Equity (avg)
-1.43
Sales to Capital Employed (avg)
1.17
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
82.56%
ROE (avg)
67.93%
Valuation Key Factors 
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
-1.91
EV to EBIT
7.34
EV to EBITDA
7.22
EV to Capital Employed
7.88
EV to Sales
2.94
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
107.34%
ROE (Latest)
Negative BV
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Technical Movement
23What is working for the Company
PRE-TAX PROFIT(Q)
At USD 65.13 MM has Grown at 188.57%
NET PROFIT(Q)
At USD 40.75 MM has Grown at 262.39%
NET SALES(Q)
At USD 106.51 MM has Grown at 43.85%
RAW MATERIAL COST(Y)
Fallen by -0.76% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -173.56 %
OPERATING PROFIT MARGIN(Q)
Highest at 68.52 %
EPS(Q)
Highest at USD 0.24
-3What is not working for the Company
INTEREST(Q)
Highest at USD 9.14 MM
Here's what is working for Ironwood Pharmaceuticals, Inc.
Pre-Tax Profit
At USD 65.13 MM has Grown at 188.57%
over average net sales of the previous four periods of USD 22.57 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 40.75 MM has Grown at 262.39%
over average net sales of the previous four periods of USD 11.24 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 106.51 MM has Grown at 43.85%
over average net sales of the previous four periods of USD 74.04 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit Margin
Highest at 68.52 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
EPS
Highest at USD 0.24
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -173.56 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -0.76% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Ironwood Pharmaceuticals, Inc.
Interest
At USD 9.14 MM has Grown at 15.91%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Interest
Highest at USD 9.14 MM
in the last five periods and Increased by 15.91% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)






